Safranal, contained in Crocus sativus L., exerts anti-inflammatory and analgesic effects. However, the underlying mechanisms for such effects are poorly under- 
used to treat headache. 5 Preclinical studies focused on the pharmacological activity of saffron and its purified constituents, suggesting anti-oxidant, 6 anti-inflammatory 7 and antinociceptive 8 properties of the golden spice. Antinociceptive effect of safranal has been demonstrated in models of inflammatory pain, such as formalin, acetic acid or carrageenan, 8 and in models of neuropathic pain, including chronic constriction injury and nerve crush injury. 9, 10 The analgesic action of safranal has been attributed to its ability to suppress glial activation and proinflammatory cytokines production in the central nervous system. 11 However, the underlying mechanisms responsible for the analgesic action of saffron have not been yet elucidated.
Transient receptor potential (TRP) channels are pleiotropic excitatory ion channels present in a large variety of cells. Some TRPs are highly expressed by specific subpopulations of primary sensory nociceptive neurons, where they contribute to sensing noxious chemical, mechanical and thermal stimuli. [12] [13] [14] In particular, the TRP ankyrin 1 (TRPA1) is coexpressed with the vanilloid type 1 (TRPV1, the capsaicin receptor), or the vanilloid type 4 (TRPV4) by a subpopulation of nociceptors, which contain and release the proinflammatory neuropeptide calcitonin gene-related peptide (CGRP) and substance P (SP). 12, 13 CGRP and SP released from peripheral endings of primary afferents mediate neurogenic inflammation 13 and CGRP is now recognized to play an essential role in migraine pain. 13, 15 TRPA1 is activated by a number of exogenous irritant and pungent agents, including allyl isothiocyanate (AITC), cinnamaldehyde 16, 17 and formalin. 18 Notably, reactive oxygen, nitrogen and carbon species gate TRPA1 by reacting with specific cysteine/lysine residues, thus mediating pain and neurogenic inflammation. [19] [20] [21] [22] [23] Here, we evaluated whether the three main constituents of saffron affect the function of TRP channels expressed in nociceptors, and in particular that of TRPA1. We found that safranal and its precursor, picrocrocin, but not crocin, selectively activate TRPA1, but not TRPV1 or TRPV4, safranal being far more effective than picrocrocin. In addition, safranal behaves as a partial agonist on TRPA1 as compared to the full agonist, AITC. Finally, safranal induces selective desensitization of the TRPA1 channel, thus attenuating neuronal excitation that results in nociception and CGRP release. This unforeseen TRPA1-desensitization mechanism could possibly explain the analgesic effects attributed to saffron.
| MATERIALS AND METHODS

| Animals
In vivo experiments and tissue collection were carried out according and water) and were allowed to acclimatize for at least 7 days prior to experimentation. Animal studies were reported in compliance with the ARRIVE guidelines. 24, 25 A group size of six animals for behavioural experiments was determined by sample size estimation using (hTRPV4-HEK293) were cultured as previously described. 28 Human foetal lung fibroblasts (IMR90; American Type Culture Collection;
, which express the native TRPA1 channel, were cultured as previously described. 29 Cells were plated on glass-coated (poly-L-lysine, 8.3 μmol/L) coverslips and cultured for 1-2 days before being used for recordings.
| Isolation of primary sensory neurons
Primary dorsal root ganglion (DRG) neurons were isolated from adult Sprague-Dawley rats and Trpa1 +/+ and Trpa1 −/− mice, and cultured as previously described. 30 Briefly, DRG were bilaterally excised and transferred to Hank's Balanced Salt Solution containing trypsin
(1 mg/mL) and collagenase type 1A or papain (both, 2 mg/mL), for rat or mouse ganglia respectively (35 minutes, 37°C). Ganglia were then transferred to warm Dulbecco's Modified Eagle Medium supplemented with 10% foetal bovine serum, 10% horse serum, 2 mmol/L L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin and 
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Neurons were then plated on glass coverslips coated with poly-Llysine (8.3 μmol/L) and laminin (5 μmol/L). 
| Cellular recordings
| Organ bath assay
Rat urinary bladder was excised from rat, and longitudinal strips were suspended at a resting tension of 1 g in 10-mL organ bath 
| CGRP-like immunoreactivity assay
| Drugs and reagents
acetamide] was synthesized as previously described. 32 If not otherwise indicated, all other reagents were obtained from Sigma-Aldrich (Milan, Italy).
| Statistical analysis
Statistical analysis was performed using the unpaired two-tailed Student's t test for comparisons between two groups and the one-or two-way ANOVA, followed by the post-hoc Bonferroni's test for comparisons of multiple groups (GraphPad Prism version 5.00, San Diego, CA, USA). A P < 0.05 was considered statistically significant.
Data are reported as mean ± SEM. to its vehicle ( Figure 1C ).
Further investigation was limited to safranal, the most potent of the three compounds. The non-electrophilic agonist, menthol, evoked a robust calcium response in 3C/K-Q hTRPA1-HEK293 cells, which express a mutant form of the TRPA1 receptor, lacking three key cysteine (C619, C639, C663) and one lysine (K708) residues, which are required for channel activation by electrophilic agonists 23, 33 ( Figure 1D ).
However, safranal failed to induce any calcium response in 3C/K-Q hTRPA1-HEK293 cells ( Figure 1D ). Finally, in IMR90 cells, which constitutively express the native human TRPA1 receptor, 34 Figure 2C ), while the response to capsaicin was unchanged in both mice strains.
| Safranal causes neuropeptides release and acute pain via TRPA1 activation in nociceptors
There is evidence that TRPA1 is localized in peptidergic primary sensory neurons. 35, 36 Central and peripheral endings of primary sensory neurons are widely expressed in most tissues and organs, including rat urinary bladder and rat or mouse spinal cord, where upon stimulation they release proinflammatory neuropeptides, such as CGRP Safranal caused a concentration-dependent contractile response of isolated strips of rat urinary bladder with a slightly lower potency than AITC (EC 50s were 76 ± 0.07 μmol/L and 56 ± 0.02 μmol/L respectively) ( Figure 3A) . Efficacy of safranal was also lower than that of AITC (maximum response, 15.5% ± 3.0% of carbachol, n = 6, and 35.1% ± 6.2% of carbachol respectively, n = 6, P < 0.05) (Figure 3A) . The response of safranal was attenuated by pre-exposure to a combination of NK1 and NK2 receptor antagonists (L-733,060 and SR48968 respectively), by pre-exposure to a high concentration of capsaicin able to desensitize the nociceptors and by pre-exposure to the TRPA1 selective antagonist, HC-030031, while it was unaffected by pre-exposure to capsazepine (TRPV1 antagonist) and HC-067047 (TRPV4 antagonist) ( Figure 3A ). This finding supports the hypothesis that safranal behaves as a partial agonist at the TRPA1 channel.
Safranal elicited a concentration-dependent increase in CGRP-LI outflow from rat spinal cord slices which was absent in a calciumfree medium or in tissues pre-exposed to a desensitizing concentration of capsaicin and in the presence of HC-030031 ( Figure 3B ). 
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These ex vivo findings were replicated in an in vivo setting.
Injection of safranal (0.2-20 nmol) into the mouse paw (20 μL, i.pl.) evoked a dose-dependent acute nociceptive response ( Figure 3D ). Figure 3G,H) . Similarly, the nociceptive response to safranal was unaffected by pretreatment with TRPV1
and TRPV4 antagonists (capsazepine and HC-067047 respectively) ( Figure 3E ).
| In vitro and in vivo exposure to safranal attenuated TRPA1-mediated responses
In hTRPA1-HEK293 transfected cells, inward currents evoked by AITC underwent a concentration-dependent attenuation after preexposure to increasing concentrations of safranal ( Figure 4A ), whereas KCl-evoked currents were not affected ( Figure 4A ). In cultured rat DRG neurons, pre-exposure to safranal reduced inward currents evoked by AITC, but not currents evoked by capsaicin, suggesting that safranal promotes selective TRPA1 desensitization (Figure 4B ). Specific desensitization of TRPA1 was also observed in organ bath experiments. Pre-exposure to safranal reduced contractile responses of rat urinary bladder strips evoked by safranal and AITC, but not those evoked by capsaicin, GSK1016790A or carbachol (Figure 4C) . Finally, pre-exposure to safranal was able to markedly reduce CGRP release from rat spinal cord evoked by AITC, without affecting the release evoked by capsaicin or GSK1016790A
( Figure 4D ).
To test whether pre-exposure to safranal could desensitize TRPA1-mediated responses in vivo, safranal was administered by the Peptidergic sensory neurons expressing TRPA1 exert a dual afferent and efferent role, because upon stimulation they can both signal pain to the brain and release from their peripheral terminals the neuropeptides SP and CGRP, which mediate neurogenic inflammatory responses. 13, 39 One of these responses is the SP-mediated contraction of rat urinary bladder smooth muscle, 40 which can be also produced by TRPA1 activation in intramural sensory nerve terminals. 37 Here, we found that safranal produced a contraction mechanistically similar to that induced by AITC, because it was abrogated after exposure to a high, desensitizing, concentration of capsaicin, in the presence of a TRPA1 selective antagonist and in the presence of a combination of NK1 and NK2 receptor antagonists. Notably, the efficacy of safranal to target TRPA1 in the urinary bladder was lower than that of AITC, further supporting a possible partial agonism of the compound.
Results obtained in vitro were recapitulated in an in vivo setting, where the proalgesic action of safranal was mediated exclusively by TRPA1. Intraplantar injection of safranal elicited a concentration-dependent acute nociceptive response that was TRPA1-dependent, being selectively attenuated by TRPA1 antagonism and gene deletion. However, there is also indication that saffron has beneficial effect in certain pain conditions. 3, 41 Furthermore, safranal has been reported to attenuate pain-like responses in animal models of inflammatory and neuropathic pain. [8] [9] [10] In particular, safranal attenuated mechanical allodynia and thermal hyperalgesia in a chronic constriction injury model, 10 suppressed the second phase of the orofacial pain induced by formalin 42 and the late phase of the carrageenan-induced paw oedema. 8 The apparent contradiction between these findings and the ability of safranal to excite the 19 Thus, it is possible that safranal exerts its partial agonist and desensitizing activities at the Schwann cell TRPA1, contributing in this manner to reduce neuropathic pain.
Clinical investigations with saffron has reported headache as a possible adverse reaction. 4 In contrast with this observation, saffron has been used by Indian traditional medicine to treat headaches. 
